

PLIVA Acquires Uso Racional in Spain

Zagreb, Croatia, 15 February 2006 – PLIVA d.d. (LSE: PLVD) announced today that an agreement has been signed with Novartis' generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L (UR) for a total cash consideration of EUR 21.5m. With expected sales of about EUR 12m in 2006, UR represents a well known and established generics brand in Spain, with a small dedicated sales force and a complementary product portfolio and attractive pipeline. The acquisition of UR represents a strong strategic fit with PLIVA's current Spanish operations, which PLIVA expects to help it significantly strengthen its position and performance on this market.

More information about PLIVA can be found at www.pliva.com

For additional information, please contact:

Marija Mandić
Executive Director
Investor Relations & Corporate Communications
Tel: +385 1 6160 355
Tel: +385 1 6120 909
Fax: +385 1 6114 413
E-mail: Marija.Mandic@pliva.com

This release contains certain "forward-looking statements", relating to the Group's business, which can be identified by the use of forward-looking terminology such as "will", "planned", "expectations", "forecast" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of new products expected to be introduced or have been introduced by the Group companies and anticipated customer demand for such products. Such statements reflect the current views of the Group with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Group to be materially different from any future results that may be expressed or implied by such forward-looking statements.